News
AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases
CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding patterns of target proteins with existing compound molecules in order to identify those with the highest chance of success in clinical trials, according to the release.
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...
Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...
Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...
AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...
This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...
Astrazeneca (AZN) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.94%. On the other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback